Zevra Therapeutics Inc (ZVRA) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Zevra Therapeutics to Participate at Upcoming Investor Events

CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the...

Form 8-K - Current report

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered...

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the...

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or...

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety...

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or...

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful...

US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise

U.S. index futures are nearly unchanged in pre-market trading this Thursday. The indexes are on track to close...

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information...